[Pubmed] Cost-effectiveness analysis of efgartigimod vs chronic immunoglobulin for the treatment of myasthenia gravis in
Posté : 27 oct. 2025 11:00
Can J Neurol Sci. 2025 Oct 27:1-37. doi: 10.1017/cjn.2025.10449. Online ahead of print.
NO ABSTRACT
PMID:41139802 | DOI:10.1017/cjn.2025.10449
Source: https://pubmed.ncbi.nlm.nih.gov/4113980 ... 22+67771e2